THC Global Group Ltd (ASX:THC)

THC Global Group Ltd (ASX:THC)


Share Price
$ 0.46
Change
-0.015 (-3.19 %)
Market Cap
$40.84 m
Proactive Investors - Run By Investors For Investors

THC Global Group Ltd

THC Global Group Ltd (ASX:THC), formerly The Hydroponics Company Ltd operates under a pharmaceutical model and is currently delivering high quality medicinal cannabis products to Australian patients through the existing access schemes.

EPIC: THC
Market: ASX:THC
52-week High/Low: A$1.120 / A$0.430
Sector: Cannabis
Market Cap: A$40.84M
Website: www.thcl.com.au
col 3
col 4
col 5
col 6

Big picture - Why invest in THC Global Group Ltd


THC Global Group Ltd Snapshot

THC has rapidly grown to become Australia’s Leading Medicinal Cannabis Company.

THC operates under a ‘farm to pharma’ pharmaceutical model and is currently delivering high quality medicinal cannabis products to Australian patients through existing access schemes. Having secured both a significant growing capacity over two grow sites, and an industry-leading pharmaceuticals biomanufacturing facility, THC is in prime position to service both domestic patients and the export market.

THC’s global commercial partners operate across four continents, supporting THC’s future international growth. THC also operates a revenue generating global hydroponics business, focusing on the manufacturing and distribution of hydroponics equipment, materials, and nutrients.

Steven Xu
Chairman

Steven is a Chartered Accountant (CA ANZ) with over 15 years’ experience working in PricewaterhouseCoopers and listed companies in Australia and China. He specialises in financing, IPO and M&A activities in a broad range of sectors including technology, agriculture, smart manufacturing and healthcare. Steven is the head of the MY INP Venture Capital Fund with global investments in Medicinal Cannabis and related industry companies. He has strong international connections, especially in North America, Israel and China, and continues to analyse and seek out investment opportunities in these industry sectors.


Alan Beasley
Non Executive Director

Alan has worked in the Investment Banking and Investment Management industries for over 30 years, with Bankers Trust Australia, Goldman Sachs Asset Management, and BNP Paribas Asset Management Ltd - the last two positions as Managing Director and Australian Country Head. Alan is a director and former director of several listed and unlisted public and private companies. Alan graduated with a Bachelor of Economics, (UNE) and completed an Advanced Management Program in International Investment Management, from the Graduate Business School, Stanford University, USA. Alan is a Certified Practising Accountant, (CPA) Fellow of the Governance Institute of Australia, (FGIA) and Fellow of the Australian Institute of Company Directors (FAICD).


Lou Cattelan
Non Executive Director

Lou has over 30 years’ experience in Pharmaceutical, Nutraceutical, Complementary Healthcare and allied industry sectors. He specialises in Project Management, Operations, Quality Assurance, Supply Chain, Strategic Planning, New Product Development, Regulatory Compliance(TGA & FDA), Sales & Marketing, Business Development and Special Projects. Lou sat on the ASMI (Australian Self Medication Industry – which is the peak industry Body for Australian Pharmaceuticals) Committee for Complementary Medicines to act as a liaison between TGA and key industry stakeholders. Lou is currently a Director of Contract Pharmaceutical Services of Australia (CPSA) as well as their Sales & Marketing Director. During his 17 years at CPSA he has consulted with all major Pharma companies including Pfizer, MSD, Mylan and GSK to take innovative concepts through to compliant finished products. He has also worked in senior hands-on positions with Ella Bache, Milpharma, Sunspot Products, Bayer Pharma and Blackmores.


Gary Radcliff
Non Executive Director

Gary is a practicing Barrister, having been called to the Bar in 1984 and is the President of the Gold Coast Bar Association. Gary is also a specialist adjudicator in relation to Dispute Resolution recognised by the Office of the Commissioner for Body Corporate and Community Management (Queensland, Australia). Gary provides a wealth of experience in corporate governance and compliance matters in both Australia and internationally. In addition to his legal practice, Gary has significant experience in project management, corporate advisory and company directorship in a wide range of sectors, most notably; pharmaceuticals, financial services and technology.


Henry Kinstlinger
Company Secretary

Henry Kinstlinger has in the past thirty years been actively involved in the financial and corporate management of several public companies and non-governmental organisations. He is a professional company secretary and corporate consultant with broad experience in investor and community relations and corporate and statutory compliance.


Last updated 23rd November 2018

Registered Office

Level 2,
131 Macquarie St
Sydney NSW 2000
 

Phone: +61 (0)2 9251 7177

Video RSS

Videos

VIEW ALL VIDEOS

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use